BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38461903)

  • 1. Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach.
    Zhang Z; Lu T; Zhang Z; Liu Z; Qian R; Qi R; Zhou F; Li M
    Biochem Pharmacol; 2024 Apr; 222():116117. PubMed ID: 38461903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells.
    Zhang Z; Shen C; Zhou F; Zhang Y
    Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
    Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
    Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin F
    Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
    World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of chemotherapeutic agents on liver microenvironment: oxaliplatin create a pro-metastatic landscape.
    Ma Y; Guo C; Wang X; Wei X; Ma J
    J Exp Clin Cancer Res; 2023 Sep; 42(1):237. PubMed ID: 37697332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway.
    Huang C; Zhou T; Ma L; Zhao S
    Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
    Gao R; Fang C; Xu J; Tan H; Li P; Ma L
    Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells.
    Wang M; Xiang Y; Wang R; Zhang L; Zhang H; Chen H; Luan X; Chen L
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36431875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PMEPA1 induces EMT via a non-canonical TGF-β signalling in colorectal cancer.
    Zhang L; Wang X; Lai C; Zhang H; Lai M
    J Cell Mol Med; 2019 May; 23(5):3603-3615. PubMed ID: 30887697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kruppel-like factor 5 enhances proliferation, lipid droplet formation and oxaliplatin resistance in colorectal cancer by promoting fatty acid binding protein 6 transcription.
    Zuo Q; Xu Q; Li Z; Luo D; Peng H; Duan Z
    Anticancer Drugs; 2023 Nov; 34(10):1171-1182. PubMed ID: 37067981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
    Zhang J; Li C; Sun L; Sun D; Zhao T
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway.
    Yin J; Wang L; Wang Y; Shen H; Wang X; Wu L
    Onco Targets Ther; 2019; 12():3893-3903. PubMed ID: 31190888
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model.
    Wang W; Wu L; Zhang J; Wu H; Han E; Guo Q
    Biochem Biophys Res Commun; 2017 May; 487(1):1-7. PubMed ID: 28042031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
    Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
    J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin inhibits colorectal cancer progression by inhibiting CXCL11 secreted by cancer-associated fibroblasts and the CXCR3/PI3K/AKT pathway.
    Lu C; Zhang C
    Clin Transl Oncol; 2023 Jan; 25(1):160-172. PubMed ID: 36129606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Synergistic effect of polysaccharide from
    Li P; Yuan P; Que Y; Liu X; Wang G
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Apr; 41(4):504-513. PubMed ID: 33963708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Cyanidin-3-
    Kurter H; Basbinar Y; Ellidokuz H; Calibasi-Kocal G
    Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell.
    Wang Z; Sun X; Feng Y; Wang Y; Zhang L; Wang Y; Fang Z; Azami NLB; Sun M; Li Q
    Phytomedicine; 2021 Feb; 82():153414. PubMed ID: 33461143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structural maintenance of chromosomes 5 is a possible biomarker for individualized treatment of colorectal cancer.
    Gong X; Tian X; Xie H; Li Z
    Cancer Med; 2023 Feb; 12(3):3276-3287. PubMed ID: 35894836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IRF-1 mediated long non-coding RNA PVT1-214 promotes oxaliplatin resistance of colorectal cancer via miR-128 inhibition.
    Tong D; Zou E; Bai L; Ma J; Guo N; Wang H; Jiang L
    J BUON; 2020; 25(5):2205-2214. PubMed ID: 33277837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.